Schonfeld Strategic Advisors LLC Acquires 36,294 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Schonfeld Strategic Advisors LLC increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 20.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,480 shares of the company's stock after purchasing an additional 36,294 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 0.33% of Kymera Therapeutics worth $8,669,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Franklin Resources Inc. increased its holdings in shares of Kymera Therapeutics by 35.1% during the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company's stock valued at $1,356,000 after acquiring an additional 7,647 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after acquiring an additional 95,547 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock valued at $1,649,000 after buying an additional 684 shares during the last quarter. Blue Trust Inc. increased its position in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after purchasing an additional 270 shares during the period. Finally, KBC Group NV boosted its stake in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares in the last quarter.

Insiders Place Their Bets

In other news, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. The trade was a 2.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,659 shares of company stock valued at $324,567. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Stock Down 3.6 %

KYMR stock traded down $1.22 during midday trading on Tuesday, reaching $32.36. 310,586 shares of the company's stock traded hands, compared to its average volume of 556,563. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -13.94 and a beta of 2.18. The firm's fifty day moving average price is $29.64 and its 200-day moving average price is $38.03.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Citigroup assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target on the stock. HC Wainwright upped their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Stephens restated an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.